{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Donanemab", "query": { "intervention": "Donanemab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Donanemab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T21:58:32.483Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05026866", "title": "A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Donanemab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "55 Years to 80 Years" }, "enrollment_count": 2996, "start_date": "2021-08-27", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 198, "location_summary": "Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 163 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05026866" }, { "nct_id": "NCT07167966", "title": "Alzheimer's Tau Platform: Regimen A - AADvac1", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Preclinical Alzheimer's Disease", "Prodromal Alzheimer's Disease", "Alzheimer Disease" ], "interventions": [ { "name": "AADvac1", "type": "DRUG" }, { "name": "Donanemab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paul S. Aisen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 450, "start_date": "2026-11-03", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07167966" }, { "nct_id": "NCT06957418", "title": "Alzheimer's Tau Platform: Master Protocol", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Preclinical Alzheimer's Disease", "Alzheimer Disease", "Prodromal Alzheimer's Disease" ], "interventions": [ { "name": "AADvac1", "type": "DRUG" }, { "name": "Tau2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paul S. Aisen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 900, "start_date": "2026-07-06", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06957418" }, { "nct_id": "NCT03367403", "title": "A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Donanemab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LY3202626", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "60 Years to 85 Years" }, "enrollment_count": 272, "start_date": "2017-12-18", "completion_date": "2021-09-21", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 56, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 47 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03367403" }, { "nct_id": "NCT05108922", "title": "A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mild Cognitive Impairment (MCI)", "Alzheimer Disease" ], "interventions": [ { "name": "Donanemab", "type": "DRUG" }, { "name": "Aducanumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 148, "start_date": "2021-11-16", "completion_date": "2023-09-19", "has_results": true, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 31, "location_summary": "Fullerton, California • Irvine, California • Sherman Oaks, California + 27 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlantis", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05108922" }, { "nct_id": "NCT06566170", "title": "A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Donanemab", "type": "DRUG" }, { "name": "Usual Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 6250, "start_date": "2024-10-07", "completion_date": "2033-02", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 1, "location_summary": "Huntsville, Alabama", "locations": [ { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06566170" }, { "nct_id": "NCT04640077", "title": "A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease", "Dementia", "Brain Diseases", "Central Nervous System Diseases", "Cognitive Impairment" ], "interventions": [ { "name": "No Intervention", "type": "OTHER" }, { "name": "donanemab", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "60 Years to 90 Years" }, "enrollment_count": 95, "start_date": "2020-11-23", "completion_date": "2024-02-27", "has_results": true, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Irvine, California • Bradenton, Florida + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Merritt Island", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04640077" }, { "nct_id": "NCT05738486", "title": "A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease", "Dementia", "Brain Diseases", "Central Nervous System Diseases", "Nervous System Diseases", "Neurodegenerative Diseases", "Neurocognitive Disorders", "Mental Disorders" ], "interventions": [ { "name": "Donanemab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "60 Years to 85 Years" }, "enrollment_count": 1175, "start_date": "2023-02-28", "completion_date": "2027-05", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 43, "location_summary": "Chandler, Arizona • Irvine, California • Long Beach, California + 38 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Atlantis", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05738486" }, { "nct_id": "NCT07602582", "title": "A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer Disease", "Dementia", "Plaque, Amyloid" ], "interventions": [ { "name": "Donanemab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 550, "start_date": "2026-05-22", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 52, "location_summary": "Phoenix, Arizona • Huntington Beach, California • Irvine, California + 45 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07602582" }, { "nct_id": "NCT07756294", "title": "Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Insulin", "type": "DRUG" }, { "name": "Insulin Placebo", "type": "DRUG" }, { "name": "Empagliflozin Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2026-09", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-02T21:58:32.483Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07756294" } ] }